The Impact of Fasting the Holy Month of Ramadan on Colorectal Cancer Patients and Two Tumor Biomarkers: A Tertiary-Care Hospital Experience.

(Short title: Intermittent Fasting and Colorectal Cancer Patients)

Kanaan Alshammari\textsuperscript{1,3,4}, Haifa Alhaidal\textsuperscript{2}, Reem Alharbi\textsuperscript{3}, Alanood Alrubai'aan\textsuperscript{3}, Ghadah Alyousif\textsuperscript{1}, Mohammad Alkaiyat\textsuperscript{1}, Wesam Abdel-Razaq\textsuperscript{2,4*}

\textsuperscript{1} King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

\textsuperscript{2} College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

\textsuperscript{3} College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

\textsuperscript{4} King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

\textbf{*Corresponding author:} Dr. Wesam S. Abdel-Razaq, Ph.D., Email: razaqw@ksau-hs.edu.sa, abdel-razaqwe@ngha.med.sa

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

**Background:** Fasting during the holy month of Ramadan is a religious ritual practiced by the majority of Muslims around the globe. This daytime fasting is short-term or intermittent fasting, which may be associated with valuable health benefits, particularly in cancer patients.

**Methods:** A prospective cohort study of pre- and post-evaluation of 37 colorectal cancer (CRC) patients was conducted in the oncology outpatient clinics to assess the impact of fasting during Ramadan on the tolerability of chemotherapy side effects and to assess changes in the levels of carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) tumor biomarkers. **Result:** The vast majority of CRC patients (89.2%) had fasted at least part of the month of Ramadan. Most (73%) reported “Serenity” after fasting during Ramadan with improved tolerability of chemotherapy side effects. The results did not reveal any significant difference in the measured laboratory variables between pre-fasting values and by the end of the 30 days of Ramadan. Although statistically insignificant, the levels of CEA and LDH were reduced in 46.9% and 55.6% of CRC patients, respectively. The mean level of CEA in the fasting group was substantially reduced by more than 40%, attributed to the highly significant decline of CEA levels in three patients only (p=0.0283). **Conclusion:** The current study confirms the safety and tolerability of intermittent fasting in CRC patients actively receiving chemotherapy, which is consistent with several reports. Nonetheless, the results did not reveal a significant decrease in CEA and LDH tumor biomarkers.

**Keywords:** Intermittent Fasting, Colorectal Cancer, Tumor Biomarkers, Carcinoembryonic Antigen (CEA), Lactate Dehydrogenase (LDH)
Introduction

Daytime fasting during the month of Ramadan is a religious ritual practiced by the majority of Muslims around the globe. Ramadan is the ninth month of the lunar, also known as the Hijri calendar. Ramadan fasting is considered a distinctive model of intermittent fasting that refrains eating and drinking all forms of foods, beverages, and even oral medications from sunrise to sunset each day until the end of the month of Ramadan, which may extend for 29 or 30 days depending on the visibility of the crescent moon. Such changes in the daily diet pattern may dramatically affect individual metabolic functions [1]. Several studies have reported valuable beneficial outcomes for intermittent fasting, including controlling obesity [2], energy metabolism [3], blood pressure [4], diabetes [5], cancer [6], and other diseases. Although Muslims worldwide are fasting the holy month of Ramadan on an annual basis, the health consequences of such lifestyle practices are not adequately studied. Therefore, it is pivotal to evaluate the safety of this fasting practice in individuals with compromised health conditions, particularly cancer patients who are receiving cytotoxic chemotherapy.

In the Gulf countries, including Saudi Arabia, colorectal cancer (CRC) is still the topmost commonly diagnosed cancer in men and the third most common cancer, after breast and thyroid cancer, in women [7]. Although CRC is usually diagnosed in the elderly population, recently, the incidence rate has peculiarly increased in younger adults under 50 years [8] [9]. Several therapeutic modalities were employed in treating CRC patients, including surgery, radiation, and systemic chemotherapy, primarily depending on the cancer stage and patient’s factors. Chemotherapy regimens were shown to be favorably effective in advanced CRC stages [10]. However, cytotoxic chemotherapies have always been associated with numerous toxicities and adverse events. These include, but are not limited to, nausea and vomiting, myelosuppression, cardiotoxicity, renal impairment, fatigue, peripheral neuropathy, and others.
This study assessed the impact of fasting during the holy month of Ramadan on CRC patients concerning their tolerability of chemotherapy side effects, besides changes in blood parameters and levels of two tumor biomarkers [namely, carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH)], which are primarily associated with certain types of carcinomas, including CRC.

### Methods

#### Study design

A prospective cohort study of pre- and post-medical and clinical evaluation of histologically confirmed CRC patients was conducted in the oncology outpatient clinics at King Abdulaziz Medical City (KAMC) and King Abdullah Specialized Children Hospital (KASCH), Riyadh, Saudi Arabia. A total of thirty-seven (37) CRC patients were followed from the beginning of the month of Ramadan until the 20th of the next Hijri month of Shawal. Patients’ demographic information including age, gender, weight, height, health status, and the received chemotherapies were retrieved from patients’ electronic medical records. Baseline clinical data, including complete blood count, renal and liver functions, and serum level of two tumor biomarkers (CEA and LDH) were measured immediately before the beginning of the fasting month of Ramadan and by the end of the follow-up period. After obtaining their informed consent, all patients were asked to fill in a mini questionnaire-based survey that explored their practice and attitudes towards fasting during the month of Ramadan, whether they complied with healthcare providers’ recommendations, and their subjective responses regarding tolerance of chemotherapy adverse effects.

#### Statistical analysis
Results are expressed as mean ± standard deviation (SD) and median with interquartile range (IQR) as dispersion characteristic for continuous data. Categorical variables are represented as proportions of total contributors. Graphs and statistical analyses were performed using GraphPad Prism® software package version 9.0 (San Diego, CA, USA). Statistical significance was considered at p-values less than 0.05 using Unpaired Student’s t-test between groups or Wilcoxon matched-pairs Student’s t-test” within the same group.

**Results**

A total of 37 CRC patients’ data were reviewed. Table-1 displays the general characteristics of enrolled patients. The mean age was 52.7 ± 11.6 years, with a median value of 53 years (range 30-76). Almost half of the sample (45.9%) were overweight or obese patients with body mass indices of more than 25. Most of the sample had advanced stage III or IV carcinomas (27.0% and 67.6%, respectively). Most patients were treated with 5-fluorouracil-based chemotherapies (FOLFOX or FOLFIRI regimen, that included fluorouracil and leucovorin added to either oxaliplatin or irinotecan) as the standard of care treatment of advanced CRC. A bit more than 50% of patients also received a biological targeted therapy (Cetuximab n=8, Bevacizumab n=8, and Panitumumab n=2) in addition to their primary standard cancer chemotherapy.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>17 (45.9%)</td>
</tr>
<tr>
<td>Female</td>
<td>20 (54.1%)</td>
</tr>
<tr>
<td><strong>Age (in years)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>52.7 ± (11.6)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>53 (30-76)</td>
</tr>
<tr>
<td><strong>BMI n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>&lt; 18.5 (underweight)</td>
<td>4 (10.8%)</td>
</tr>
<tr>
<td>18.5-24.9 (healthy weight)</td>
<td>16 (43.2%)</td>
</tr>
<tr>
<td>Smoking n (%)</td>
<td>No</td>
</tr>
<tr>
<td>Hypertension n (%)</td>
<td>No</td>
</tr>
<tr>
<td>Hyperlipidemia n (%)</td>
<td>No</td>
</tr>
<tr>
<td>Diabetes n (%)</td>
<td>No</td>
</tr>
<tr>
<td>CA Family History n (%)</td>
<td>No</td>
</tr>
<tr>
<td>ECOG Performance Status n (%)</td>
<td>0</td>
</tr>
<tr>
<td>Tumor site n (%)</td>
<td>Colon</td>
</tr>
<tr>
<td>Cancer Stage n (%)</td>
<td>II</td>
</tr>
</tbody>
</table>

Patients were asked to fill in a mini-questionnaire survey exploring their fasting practice during the month of Ramadan (data not shown). About 92% of patients had consulted with their healthcare providers about the safety and appropriateness of fasting during the month of Ramadan, which coincided with their chemotherapy cycles. Almost all healthcare providers assured the safety of such intermittent fasting on CRC patients. Nearly one-third of patients had asked for dose rescheduling after sunset so that it would not affect their fasting practice during the daytime. In general, most patients (73%) reported “Serenity” after fasting during the holy month of Ramadan with perceived improved tolerability of chemotherapy side effects. About
8% of patients had unplanned visits to the emergency room during the month of Ramadan due to either pain or fever; one patient reported a skin rash. Less than 20% of responders reported feeling nauseous while fasting, but it did not affect their activities of daily living in most patients. This was confirmed by the Eastern Cooperative Oncology Group (ECOG) performance status scale, which determines patients’ ability to carry out their daily living activities during cancer chemotherapy and is reported by the treating physician (for details, see Table-1).

The vast majority of patients (89.2%, n=33) had fasted at least part of the month of Ramadan. On average, patients had fasted for 25 ± (5.3) days (range 10-30 days). Thus, it was decided to categorize patients into; Group A, which included patients who did not fast (n=4, 10.8%) or had fasted less than 20 days (n=7, 18.9%), and Group B, those patients who had fasted the entire 30 days of the month of Ramadan (n=13, 35.1%) or had fasted at least 20 days (n=13, 35.1%). Table-2 presents various demographic and clinical data of patients in both groups. The two groups show no significant difference, implying similar initial variables.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A</th>
<th>Group B</th>
<th>p-value (unpaired t-test)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None or fasted Less than 20 days (n=11)</td>
<td>Fasted 20 days or more (n=26)</td>
<td></td>
</tr>
<tr>
<td>Gender n (%)</td>
<td>Male</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 (54.5%)</td>
<td>5 (45.5%)</td>
<td>11 (42.3%)</td>
</tr>
<tr>
<td>Age (in years)</td>
<td>Mean ± (SD)</td>
<td>51.4 ± (11.7)</td>
<td>53.2 ± (11.8)</td>
</tr>
<tr>
<td></td>
<td>Median (range)</td>
<td>57 (31-65)</td>
<td>51.5 (30-76)</td>
</tr>
<tr>
<td>BMI n (%)</td>
<td>&lt; 18.5 (underweight)</td>
<td>2 (18.2%)</td>
<td>2 (7.7%)</td>
</tr>
<tr>
<td></td>
<td>18.5-24.9 (healthy weight)</td>
<td>4 (36.4%)</td>
<td>12 (46.2%)</td>
</tr>
<tr>
<td></td>
<td>25-29.9 (overweight)</td>
<td>3 (27.3%)</td>
<td>6 (23.1%)</td>
</tr>
<tr>
<td></td>
<td>≥ 30 (obesity)</td>
<td>2 (18.2%)</td>
<td>6 (23.1%)</td>
</tr>
<tr>
<td>Smoking n (%)</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 (90.9%)</td>
<td>1 (9.1%)</td>
<td>25 (96.2%)</td>
</tr>
<tr>
<td>Condition</td>
<td>No (%)</td>
<td>Yes (%)</td>
<td>p-value</td>
</tr>
<tr>
<td>----------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Hypertension</strong> n (%)</td>
<td>8 (72.7%)</td>
<td>19 (73.1%)</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Hyperlipidemia</strong> n (%)</td>
<td>10 (90.9%)</td>
<td>20 (76.9%)</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Diabetes</strong> n (%)</td>
<td>8 (72.7%)</td>
<td>13 (50.0%)</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>CA Family History</strong> n (%)</td>
<td>10 (90.9%)</td>
<td>23 (88.5%)</td>
<td>0.83</td>
</tr>
<tr>
<td><strong>G-CSF (Filgrastim)</strong></td>
<td>6 (54.5%)</td>
<td>10 (38.5%)</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>BSA (in g/dL)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>1.8 ± (0.4)</td>
<td>1.7 ± (0.3)</td>
<td>0.41</td>
</tr>
<tr>
<td>Median (range)</td>
<td>1.7 (1.2-2.3)</td>
<td>1.8 (1.2-2.2)</td>
<td></td>
</tr>
<tr>
<td><strong>ECOG Performance Status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4 (36.4%)</td>
<td>9 (34.6%)</td>
<td>0.95</td>
</tr>
<tr>
<td>1</td>
<td>7 (63.6%)</td>
<td>15 (57.7%)</td>
<td></td>
</tr>
<tr>
<td><strong>Hemoglobin (g/L)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>121.1 ± (13.5)</td>
<td>115.0 ± (16.6)</td>
<td>0.29</td>
</tr>
<tr>
<td>Median (range)</td>
<td>120 (105-150)</td>
<td>115.5 (88-147)</td>
<td></td>
</tr>
<tr>
<td><strong>White blood cells (x10^3 /mcL)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>6.0 ± (2.6)</td>
<td>6.2 ± (2.3)</td>
<td>0.20</td>
</tr>
<tr>
<td>Median (range)</td>
<td>5.2 (2.5-11.7)</td>
<td>5.9 (1.7-11.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Platelets (x10^3 /mcL)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>236.4 ± (149.4)</td>
<td>215.2 ± (76.5)</td>
<td>0.57</td>
</tr>
<tr>
<td>Median (range)</td>
<td>175 (68-490)</td>
<td>207 (94-450)</td>
<td></td>
</tr>
<tr>
<td><strong>eGFR (mL/min/1.73m²)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>97.0 ± (36.9)</td>
<td>103.6 ± (25.5)</td>
<td>0.53</td>
</tr>
<tr>
<td>Median (range)</td>
<td>109 (37-140)</td>
<td>103 (66-160)</td>
<td></td>
</tr>
<tr>
<td><strong>Alkaline phosphatase (IU/L)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>112.4 ± (42.7)</td>
<td>160.3 ± (98.0)</td>
<td>0.13</td>
</tr>
<tr>
<td>Median (range)</td>
<td>96 (68-193)</td>
<td>121.5 (70-416)</td>
<td></td>
</tr>
<tr>
<td>Missing data = 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEA level (ng/mL)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>15.6 ± (32.4)</td>
<td>83.4 ± (184.1)</td>
<td>0.24</td>
</tr>
<tr>
<td>Median (range)</td>
<td>2.9 (1.7-89)</td>
<td>12.1 (1.7-603)</td>
<td></td>
</tr>
<tr>
<td>Missing data = 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lactate dehydrogenase (mmol/L)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± (SD)</td>
<td>230.9 ± (121.0)</td>
<td>299.8 ± (169.4)</td>
<td>0.23</td>
</tr>
<tr>
<td>Median (range)</td>
<td>183 (129-487)</td>
<td>221.5 (154-689)</td>
<td></td>
</tr>
<tr>
<td>Missing data = 10</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
On the other hand, Table-3 shows the mean differences between initial variables and after fasting, if any, by the end of the 30 days of the month of Ramadan. The measured blood parameters were almost comparable. Although statistically insignificant, both tumor biomarkers, CEA and LDH, were reduced by 12.4% and 21.8%, respectively, in Group-A; and declined by 40.9% and 15.5%, respectively, in Group B. Nevertheless, one sample in group A showed a noteworthy decrease in CEA levels from 89 to 54 mmol/L, whereas another sample in group-A showed an increase in CEA levels from 6.9 to 29.2 mmol/L (See Figure-1). Three samples in Group B showed momentous decreases in CEA levels from a mean value of 568.3 ± (32.7) to 296.0 ± (103.6) ng/mL with a highly significant p-value of 0.0283.

Table-3: Mean difference value analysis, n = 37

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A: None or fasted less than 20 days (n=11)</th>
<th>Group B: Fasted 20 days or more (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before Mean ± (SD)</td>
<td>After Mean ± (SD)</td>
</tr>
<tr>
<td>Haemoglobin (g/L)</td>
<td>121.1 (13.5)</td>
<td>123.6 (12.0)</td>
</tr>
<tr>
<td>White blood cells (x10^3 /mcL)</td>
<td>6.0 (2.6)</td>
<td>7.4 (5.7)</td>
</tr>
<tr>
<td>Platelets (x10^3 /mcL)</td>
<td>236.4 (149.4)</td>
<td>250.4 (159.4)</td>
</tr>
<tr>
<td>eGFR (mL/min/1.73m²)</td>
<td>97.0 (36.9)</td>
<td>94.3 (32.0)</td>
</tr>
<tr>
<td>Alkaline phosphatase (IU/L) Missing data =2</td>
<td>112.4 (42.7)</td>
<td>133.7 (65.4)</td>
</tr>
<tr>
<td>CEA level (ng/mL) Missing data =5</td>
<td>15.6 (32.4)</td>
<td>13.7 (20.4)</td>
</tr>
<tr>
<td>Lactate dehydrogenase (mmol/L) Missing data =10</td>
<td>230.9 (121.0)</td>
<td>180.6 (40.7)</td>
</tr>
</tbody>
</table>

* Between means (Wilcoxon matched-pairs signed-rank test)
Group A (n=7)

Group B (n=25)

Figure-1: CEA levels (ng/mL) before versus after the end of the month of Ramadan in the low-fasting (Group A) and the high-fasting (Group B). The p-value (0.0283) is calculated for only the three samples that showed a significant reduction in CEA levels.

Discussion

Despite the notable advances in cancer treatment, cancer remains a considerable burden on the healthcare system. According to the Global Cancer Statistics 2020 (GLOBOCAN), about 19.3
116 million new cancer cases were estimated Worldwide in 2020, with 28.4 million new cases by 
117 2040 [8]. CRC is among those commonly diagnosed malignancies among adults in men and 
118 women. CRC is the third most common cancer in the US after lung and breast cancer, with 
119 incidence rates of 30% higher in men than in women [11]. Meanwhile, the overall death rate 
120 due to CRC has continued to decline over the last few decades reflecting improvement in the 
121 monitoring and treatment of CRC [8].

122 Family history and screening of intestinal adenomatous polyps before they become cancerous 
123 are pivotal for the early detection of CRC. It is usually challenging to recognize such carcinoma 
124 because it does not produce definitive classical symptoms. According to the American Society 
125 of Clinical Oncology and the European Society for Medical Oncology guidelines, regular 
126 screening of asymptomatic adults with an average risk is recommended at 50 years old [12, 13]. 
127 This age has decreased recently to 45 years due to the steady increase of CRC amongst the 
128 young. However, there are few sensitive and specific tumor biomarkers for detection and/or 
129 assessing the efficiency of anticancer therapy. Currently, tumor biomarkers are rarely used to 
130 screen cancer either due to the absence of specific biomarkers or their inconsistent expression 
131 in cancer cells. Serum carcinoembryonic antigen (CEA) is the most widely known diagnostic 
132 and prognostic tumor biomarker in recurrent CRC [14]. Lactate dehydrogenase (LDH) has also 
133 been utilized in the oncology practice as a biomarker of the tumor prognosis [15]. Both 
134 biomarkers are not specific for CRC only, as elevated levels of CEA and LDH can also be 
135 concurrent with other cancers and in several inflammatory and metabolic disorders [16, 17]. 
136 Nevertheless, CEA remains a non-invasive tumor biomarker to monitor CRC progression and 
137 the efficacy of anticancer treatment [18].

138 The current study investigated changes in the blood parameters and levels of the two tumor 
139 biomarkers [CEA and LDH] due to intermittent fasting during the month of Ramadan in CRC 
140 patients receiving chemotherapy. The results did not reveal any significant difference in the
measured variables between the initial values and by the end of the 30 days of the month of Ramadan. Although statistically insignificant, the levels of CEA and LDH were reduced in the majority of CRC patients. However, the mean level of CEA in the fasting group was substantially reduced by more than 40% attributed to the highly significant decline of CEA levels in three patients only (p=0.0283) who had remarkably extreme levels of CEA. Nonetheless, the high CEA levels were associated with poor survival in CRC patients [19].

Several studies have appraised the role of CEA tumor biomarker as a diagnostic and prognostic tool, especially in the advanced CRC stages [14, 16, 20]. Others reported suboptimal accuracy of this tumor biomarker for CRC [21, 22].

On the other hand, quite a few studies have investigated the role of LDH, a key enzyme in glycolysis, as a prognostic tumor biomarker in clinical practice [17]. High LDH levels are usually associated with significant tumor burden due to the invasiveness and chemotherapy resistance in several malignancies, including CRC [23, 24]. A recent study has employed the LDH-to-albumin ratio as a prognostic biomarker in CRC patients, which was associated with poor prognosis in CRC patients [25]. Results of the current study have revealed an insignificant decrease in the levels of LDH among CRC patients in both fasting and non-fasting groups. However, some studies reported a significant correlation between the LDH levels and chemotherapy response as well as with the overall survival in patients with high LDH levels [26, 27]. Other studies reported significant benefits of bevacizumab as a targeted therapy, when combined with the standard of care treatment of metastatic and advanced CRC in patients with high LDH levels [28].

Therefore, all these results support the potential role of CEA and LDH levels as predictive tumor biomarkers in CRC patients. Moreover, the combined assessment of these tumor biomarkers, with possibly other parameters [29], rather than relying on a single element, can
facilitate the early detection of CRC recurrence, besides their utilization as a prognostic tool
and eventually during the follow-up of anticancer therapy.

This study also investigated the potential benefits of intermittent fasting in CRC patients
receiving chemotherapy during the month of Ramadan. The majority of patients in the current
study have reported improvement in intolerability of the chemotherapy side effects. Less than
20% of patients reported worsening nausea while fasting, but it did not affect their usual
activities of daily living. This is consistent with a number of studies that have reported no
significant changes during short-term fasting [30, 31] or even a substantial reduction in the
chemotherapy-related adverse effects, particularly in hematological toxicity [32], GI upsets
[33] and fatigue [34]. Due to the hot and dry climate, dehydration and the renal and liver status
are among the critical concerns of prolonged fasting periods in the current study settings.
However, both eGFR and alkaline phosphate showed no significant changes, minimizing such
concerns.

Moreover, several reports have also suggested a potential improvement in the cancer
therapeutic outcomes if cancer chemotherapy was combined with short-term fasting due to
restriction of nutrient intake without causing weight loss [35]. Furthermore, fasting could even
augment cancer immunotherapy strategies by inducing cancer-specific T cell activation, which
plausibly enhances the cancer cell killing effect [36].

All these previous results have confirmed the safety and the potential benefit of intermittent
fasting or short-term fasting during chemotherapy due to alleviation of adverse effects and
possibly attributed to the profound metabolic changes in the human body that occurs during
nutrient restriction such as reduction of the circulating levels of growth factors, and
inflammatory cytokines that are associated with various malignancies [37, 38].
Lastly, the small sample size is an inevitable limitation of the current study limitations that may have impacted the significance and generalizability of the study results. Furthermore, it is important to report that CEA and LDH levels are not routinely measured during the adjuvant chemotherapy setting in CRC patients. Recruited patients in this study had different CRC stages, some being in the early stage (II and III) and others being in the late stage IV. Hence, the effects of fasting on CEA and LDH levels may perhaps be overestimated.

Conclusion

The results of this study have been consistent with several reports that have demonstrated the safety of intermittent fasting with enhanced tolerability and possibly improved therapeutic outcomes of cancer chemotherapy. Nonetheless, limited data explored the impact of fasting in cancer patients before verifying the potential health benefits. The levels of CEA and LDH tumor biomarkers, which are frequently associated with CRC, were not valuable in assessing the benefits of intermittent fasting during chemotherapy. Therefore, further studies with a larger population and more extended follow-up periods are still necessary to evaluate the role of CEA and LDH levels as screening, diagnostic, and prognostic tumor biomarkers or to monitor patients’ responses to anticancer therapy.

Acknowledgments

The authors would like to thank the whole team in the Oncology Department at KAMC and KASCH for their indispensable assistance during data collection.

Reference


colon cancers. PloS one. 2012;7(9):e46000. Epub 2012/10/11. doi:
10.1371/journal.pone.0046000. PubMed PMID: 23049919; PubMed Central PMCID:
PMC3457959 (Germany). The sponsor has partially supplied the reagents for the study,
performed technical training and support. The authors declare that they are not employed and
not consultants at the funder. The authors have no share in patents, products in development
or marketed products. This does not alter the authors’ adherence to all the PLOS ONE
policies on sharing data and materials.

chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells
PubMed PMID: 20144215; PubMed Central PMCID: PMC2829492.

Lactic Acid, Lactate Dehydrogenase, and Albumin Levels in Patients with Metastatic
doi: 10.1155/2018/1804086. PubMed PMID: 30627541; PubMed Central PMCID:
PMC6304480.

25. Aday U, Böyük A, Akkoç H. The prognostic significance of serum lactate

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-
22315053; PubMed Central PMCID: PMC3305976.

Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in
Patients with Metastatic Colorectal Cancer. PloS one. 2015;10(8):e0134732. Epub
2015/08/06. doi: 10.1371/journal.pone.0134732. PubMed PMID: 26244985; PubMed Central
PMCID: PMC4526665.

LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
PubMed PMID: 28081548; PubMed Central PMCID:PMC5294477 Eli-Lilly, Bayer,
Novartis, Ipsen; FL reports serving on advisory board for Amgen and Sanofi-Aventis,
receiving lecture fees from Sanofi-Aventis, Bayer, Roche and grant support from Roche and
Merck Serono; AF reports serving on advisory board for Amgen, Bayer, Merck Serono,
Roche and Sanofi-Aventis, receiving lecture fees from Merck Serono, Roche, Amgen, Bayer,
Amgen, Bayer, Merck Serono, Roche and Sanofi-Aventis and grant support from Amgen,
Merck Serono and Roche; CC reports serving on advisory board for Roche, Bayer, Amgen
and Merck Serono and receiving lecture fees from Sanofi-Aventis and Bayer. All remaining
authors declared no conflicts of interest.

CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical
Parameters for Colorectal Cancer. Scientific reports. 2018;8(1):2732. Epub 2018/02/11. doi:
369 10.1038/s41598-018-21048-y. PubMed PMID: 29426902; PubMed Central PMCID:
370 PMC5807317.
372 feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer.
374 PubMed Central PMCID: PMCPMC4901417.
378 reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse
379 PubMed PMID: 24905167; PubMed Central PMCID: PMCPMC4102383.
380
384
386 The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients
387 with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer.
389 29699509; PubMed Central PMCID: PMCPMC5921787.
390
391 35. Lee C, LongoVD. Fasting vs dietary restriction in cellular protection and cancer
394
397 Central PMCID: PMCPMC4659410.
398
399 37. de Groot S, Pijl H, van der Hoeven JJM, Kroep JR. Effects of short-term fasting on
402 PMCPMC6530042.
403
404